458 related articles for article (PubMed ID: 16440772)
21. [Pulmonary Waldenström's macroglobulinemia--a case report].
Masu M; Ishikawa T; Yabe H; Nagai K; Nakayama S
Rinsho Ketsueki; 1989 Apr; 30(4):485-90. PubMed ID: 2504976
[TBL] [Abstract][Full Text] [Related]
22. [Bing-Neel syndrome revealing Waldenström's macroglobulinemia].
Drouet T; Behin A; Psimaras D; Choquet S; Guillevin R; Hoang Xuan K
Rev Neurol (Paris); 2010 Jan; 166(1):66-75. PubMed ID: 19403149
[TBL] [Abstract][Full Text] [Related]
23. Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia.
Treon SP; Hansen M; Branagan AR; Verselis S; Emmanouilides C; Kimby E; Frankel SR; Touroutoglou N; Turnbull B; Anderson KC; Maloney DG; Fox EA
J Clin Oncol; 2005 Jan; 23(3):474-81. PubMed ID: 15659493
[TBL] [Abstract][Full Text] [Related]
24. Waldenström's macroglobulinemia: review of 45 cases.
Krajny M; Pruzanski W
Can Med Assoc J; 1976 May; 114(10):899-900, 902, 905. PubMed ID: 817791
[TBL] [Abstract][Full Text] [Related]
25. How we treat Waldenström's macroglobulinemia.
Dimopoulos MA; Merlini G; Leblond V; Anagnostopoulos A; Alexanian R
Haematologica; 2005 Jan; 90(1):117-25. PubMed ID: 15642678
[TBL] [Abstract][Full Text] [Related]
26. Diagnosis and management of Waldenstrom's macroglobulinemia.
Dimopoulos MA; Kyle RA; Anagnostopoulos A; Treon SP
J Clin Oncol; 2005 Mar; 23(7):1564-77. PubMed ID: 15735132
[TBL] [Abstract][Full Text] [Related]
27. Case of mononeuritis multiplex onset with rituximab therapy for Waldenström's macroglobulinemia.
Mauermann ML; Ryan ML; Moon JS; Klein CJ
J Neurol Sci; 2007 Sep; 260(1-2):240-3. PubMed ID: 17537458
[TBL] [Abstract][Full Text] [Related]
28. Expression of the human concentrative nucleotide transporter 1 (hCNT1) gene correlates with clinical response in patients affected by Waldenström's Macroglobulinemia (WM) and small lymphocytic lymphoma (SLL) undergoing a combination treatment with 2-chloro-2'-deoxyadenosine (2-CdA) and Rituximab.
Rabascio C; Laszlo D; Andreola G; Saronni L; Radice D; Rigacci L; Fabbri A; Frigeri F; Calabrese L; Billio A; Bertolini F; Martinelli G
Leuk Res; 2010 Apr; 34(4):454-7. PubMed ID: 19647871
[TBL] [Abstract][Full Text] [Related]
29. [(Neurological CPC-59). A 65-year-old man with a history of gastric cancer who presented progressive loss of vision, memory loss and consciousness disturbance].
Nohara C; Matsumine H; Suzuki K; Saito A; Ohtaka M; Mori H; Suda K; Kondo T; Hayakawa M; Kanai J; Mizuno Y
No To Shinkei; 1997 Nov; 49(11):1041-51. PubMed ID: 9396038
[TBL] [Abstract][Full Text] [Related]
30. Extended rituximab therapy in Waldenström's macroglobulinemia.
Treon SP; Emmanouilides C; Kimby E; Kelliher A; Preffer F; Branagan AR; Anderson KC; Frankel SR;
Ann Oncol; 2005 Jan; 16(1):132-8. PubMed ID: 15598950
[TBL] [Abstract][Full Text] [Related]
31. Lymphoplasmacytic lymphoma with IgA hypergammaglobulinemia and liver involvement.
Polprasert C; Wongchitrat C; Assanasen T; Prayongratana K
J Med Assoc Thai; 2009 Jun; 92 Suppl 3():S65-8. PubMed ID: 19702069
[TBL] [Abstract][Full Text] [Related]
32. [MALT lymphoma accompanied by elevated serum IgM levels mimicking Waldenström's macroglobulinemia].
Izumi S; Kimura K; Takeda Y; Tsukamoto S; Yamazaki M; Mishina T; Nagai Y; Takaishi K; Nagao Y; Oshima-Hasegawa N; Mitsukawa S; Mimura N; Takeuchi M; Ohwada C; Iseki T; Ota S; Nakaseko C; Sakaida E
Rinsho Ketsueki; 2018; 59(12):2600-2605. PubMed ID: 30626796
[TBL] [Abstract][Full Text] [Related]
33. Myelopathy from Waldenström's macroglobulinemia: improvement after Rituximab therapy.
Liberato B; Riethmuller A; Comenzo RL; Lis E; Raizer JJ
J Neurooncol; 2003 Jun; 63(2):207-11. PubMed ID: 12825826
[TBL] [Abstract][Full Text] [Related]
34. Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248.
Treon SP; Hunter ZR; Matous J; Joyce RM; Mannion B; Advani R; Cook D; Songer J; Hill J; Kaden BR; Sharon D; Steiss R; Leleu X; Branagan AR; Badros A
Clin Cancer Res; 2007 Jun; 13(11):3320-5. PubMed ID: 17545538
[TBL] [Abstract][Full Text] [Related]
35. Waldenstrom's macroglobulinemia in the era of immunotherapy.
Vaxman I; Gertz M
Leuk Lymphoma; 2020 Jun; 61(6):1292-1304. PubMed ID: 31960730
[TBL] [Abstract][Full Text] [Related]
36. Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group.
Chen CI; Kouroukis CT; White D; Voralia M; Stadtmauer E; Stewart AK; Wright JJ; Powers J; Walsh W; Eisenhauer E;
J Clin Oncol; 2007 Apr; 25(12):1570-5. PubMed ID: 17353550
[TBL] [Abstract][Full Text] [Related]
37. Expression of serotherapy target antigens in Waldenstrom's macroglobulinemia: therapeutic applications and considerations.
Treon SP; Kelliher A; Keele B; Frankel S; Emmanouilides C; Kimby E; Schlossman R; Mitsiades N; Mitsiades C; Preffer F; Anderson KC
Semin Oncol; 2003 Apr; 30(2):248-52. PubMed ID: 12720146
[TBL] [Abstract][Full Text] [Related]
38. [Skin abnormalities as first sign of Waldenström macroglobulinaemia].
Visser MF; Croon-de Boer F; Lonnee ER; Drees A
Ned Tijdschr Geneeskd; 2010; 154():A2097. PubMed ID: 21029489
[TBL] [Abstract][Full Text] [Related]
39. Treatment of Waldenström's macroglobulinemia with rituximab.
Dimopoulos MA; Zervas C; Zomas A; Kiamouris C; Viniou NA; Grigoraki V; Karkantaris C; Mitsouli C; Gika D; Christakis J; Anagnostopoulos N
J Clin Oncol; 2002 May; 20(9):2327-33. PubMed ID: 11981004
[TBL] [Abstract][Full Text] [Related]
40. [The treatment of Waldenström macroglobulinemia and the therapy of diseases caused by monoclonal IgM gammaglobulin].
Adam Z; Scudla V; Krejcí M; Korístek Z
Vnitr Lek; 2008 Jan; 54(1):68-83. PubMed ID: 18390120
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
